Related Experiment Video
Updated: Jan 30, 2026

Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow
Published on: January 8, 2014
PentraSorb C-Reactive Protein: Characterization of the Selective C-Reactive Protein Adsorber Resin
Stephan Mattecka1, Patrizia Brunner2, Britta Hähnel1
1Pentracor GmbH, Hennigsdorf, Germany.
Insights
A novel PentraSorb CRP adsorber effectively removes C-reactive protein (CRP), a key inflammation marker and cardiac risk factor, from human plasma. This technology shows promise for treating acute myocardial infarction and other inflammatory conditions.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Immunology
Background:
- C-reactive protein (CRP) is a significant marker of inflammation and a risk factor for cardiac events, including acute myocardial infarction (AMI).
- Previous studies in animal models suggest that reducing CRP levels through extracorporeal apheresis can mitigate tissue damage and improve cardiac function post-AMI.
- Elevated CRP levels are associated with various acute inflammatory diseases, necessitating effective therapeutic strategies.
Purpose of the Study:
- To develop and evaluate a novel adsorber, PentraSorb CRP, for the selective removal of CRP from human plasma.
- To assess the efficiency, specificity, and reusability of the PentraSorb CRP resin for clinical applications.
- To determine the potential of CRP apheresis using PentraSorb CRP as a therapeutic approach for inflammatory diseases.
Main Methods:
- Development of a novel resin-based adsorber (PentraSorb CRP) designed for specific CRP binding.
- Evaluation of CRP depletion efficiency and selectivity using Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
- Testing of the adsorber's performance across a range of CRP concentrations (10-100 mg/L) and flow rates (17-40 mL/min), and assessment of resin regenerability and biocompatibility.
Main Results:
- The PentraSorb CRP resin demonstrated highly specific binding of CRP from human plasma with minimal co-purification of other proteins.
- Efficient and selective CRP depletion was achieved across various concentrations and flow rates, comparable to small-scale and larger adsorber volumes.
- The resin maintained its CRP binding capacity and biocompatibility after up to 200 regeneration cycles.
Conclusions:
- PentraSorb CRP is a novel, specific, and efficient resin for CRP apheresis.
- The developed adsorber is suitable for clinical application in managing inflammatory conditions.
- CRP apheresis holds potential as a therapeutic strategy for patients with acute myocardial infarction, stroke, acute pancreatitis, and Crohn's disease.
Abstract:
C-reactive protein (CRP) is well known as a general marker of inflammation. It furthermore represents a reliable risk factor for cardiac events and mediates tissue damage in acute myocardial infarction (AMI). It has been demonstrated that selective CRP depletion by extracorporeal apheresis in a porcine AMI model had beneficial effects on the infarcted area and the cardiac output. We therefore developed a novel adsorber for CRP apheresis from human plasma (PentraSorb CRP). It is intended for use in the clinic as therapy for patients suffering from AMI or other acute inflammatory diseases with elevated CRP plasma levels. The PentraSorb resin specifically bound CRP from human blood plasma and almost no other proteins as determined via Sodium dodecyl sulfate polyacrylamide gel electropheresis (SDS-PAGE). The resin further efficiently and selectively depleted CRP from plasma with low as well as high CRP concentrations (10-100 mg/L) at different flow rates, ranging from 17 to 40 mL/min. The resin was regenerable for up to 200 times without losing its CRP binding capacity or affecting biocompatibility. The depletion of CRP from plasma was comparable between the utilized small-scale column (0.5 mL resin) and the PentraSorb CRP adsorber (20 mL resin volume). The established features can therefore be applied to the clinical setting. In summary, PentraSorb CRP provides a novel, specific, and efficient CRP-binding resin that could be used in apheresis therapy for patients suffering from inflammatory diseases such as AMI, stroke, acute pancreatitis, and Crohn's disease.
Related Concept Videos
Cross-reactivity
Reactivity of Enols
Reactivity of Enolate Ions
Radical Reactivity: Overview
Radical Reactivity: Nucleophilic Radicals
Radical Reactivity: Intramolecular vs Intermolecular

